Arcticzymes Technologies ASA (OL:AZT) — Market Cap & Net Worth
Market Cap & Net Worth: Arcticzymes Technologies ASA (AZT)
Arcticzymes Technologies ASA (OL:AZT) has a market capitalization of $110.71 Million (Nkr1.05 Billion) as of June 17, 2026. Listed on the OL stock exchange, this Norway-based company holds position #18897 globally and #165 in its home market, demonstrating a -1.44% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Arcticzymes Technologies ASA's stock price Nkr20.60 by its total outstanding shares 51071390 (51.07 Million). Review Arcticzymes Technologies ASA (AZT) financial obligations to assess the company's total debt and financial obligations.
Arcticzymes Technologies ASA Market Cap History: 2015 to 2026
Arcticzymes Technologies ASA's market capitalization history from 2015 to 2026. Data shows growth from $69.33 Million to $110.71 Million (4.26% CAGR).
Arcticzymes Technologies ASA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Arcticzymes Technologies ASA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.98x
Arcticzymes Technologies ASA's market cap is 0.98 times its annual revenue
Latest Price to Earnings (P/E) Ratio
11.20x
Arcticzymes Technologies ASA's market cap is 11.20 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $60.73 Million | $71.90 Million | -$20.48 Million | 0.84x | N/A |
| 2017 | $36.01 Million | $66.69 Million | -$24.94 Million | 0.54x | N/A |
| 2018 | $18.92 Million | $66.77 Million | -$13.99 Million | 0.28x | N/A |
| 2019 | $25.53 Million | $77.25 Million | -$6.39 Million | 0.33x | N/A |
| 2020 | $341.80 Million | $93.45 Million | $83.12 Million | 3.66x | 4.11x |
| 2021 | $505.17 Million | $127.97 Million | $46.38 Million | 3.95x | 10.89x |
| 2022 | $385.06 Million | $136.97 Million | $32.86 Million | 2.81x | 11.72x |
| 2023 | $225.72 Million | $118.94 Million | $19.43 Million | 1.90x | 11.62x |
| 2024 | $71.69 Million | $104.35 Million | $8.47 Million | 0.69x | 8.47x |
| 2025 | $110.71 Million | $112.62 Million | $9.88 Million | 0.98x | 11.20x |
Competitor Companies of AZT by Market Capitalization
Companies near Arcticzymes Technologies ASA in the global market cap rankings as of June 17, 2026.
Key companies related to Arcticzymes Technologies ASA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
Arcticzymes Technologies ASA Historical Marketcap From 2015 to 2026
Between 2015 and today, Arcticzymes Technologies ASA's market cap moved from $69.33 Million to $ 110.71 Million, with a yearly change of 4.26%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Nkr110.71 Million | 0.00% |
| 2025 | Nkr110.71 Million | +54.42% |
| 2024 | Nkr71.69 Million | -68.24% |
| 2023 | Nkr225.72 Million | -41.38% |
| 2022 | Nkr385.06 Million | -23.78% |
| 2021 | Nkr505.17 Million | +47.80% |
| 2020 | Nkr341.80 Million | +1238.95% |
| 2019 | Nkr25.53 Million | +34.94% |
| 2018 | Nkr18.92 Million | -47.46% |
| 2017 | Nkr36.01 Million | -40.71% |
| 2016 | Nkr60.73 Million | -12.40% |
| 2015 | Nkr69.33 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Arcticzymes Technologies ASA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $110.71 Million USD |
| MoneyControl | $110.71 Million USD |
| MarketWatch | $110.71 Million USD |
| marketcap.company | $110.71 Million USD |
| Reuters | $110.71 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Arcticzymes Technologies ASA
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays for the removal… Read more